GB0111279D0 - Radiolabelled liposomes - Google Patents

Radiolabelled liposomes

Info

Publication number
GB0111279D0
GB0111279D0 GBGB0111279.6A GB0111279A GB0111279D0 GB 0111279 D0 GB0111279 D0 GB 0111279D0 GB 0111279 A GB0111279 A GB 0111279A GB 0111279 D0 GB0111279 D0 GB 0111279D0
Authority
GB
United Kingdom
Prior art keywords
liposomes
internalised
internalisation
entrapped
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0111279.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging AS filed Critical Nycomed Imaging AS
Priority to GBGB0111279.6A priority Critical patent/GB0111279D0/en
Publication of GB0111279D0 publication Critical patent/GB0111279D0/en
Priority to AT02769160T priority patent/ATE430557T1/de
Priority to PCT/GB2002/002100 priority patent/WO2002089771A1/en
Priority to EP02769160A priority patent/EP1385480B1/en
Priority to JP2002586908A priority patent/JP4629308B2/ja
Priority to US10/477,157 priority patent/US20040170560A1/en
Priority to DE60232237T priority patent/DE60232237D1/de
Priority to ES02769160T priority patent/ES2323493T3/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
GBGB0111279.6A 2001-05-10 2001-05-10 Radiolabelled liposomes Ceased GB0111279D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0111279.6A GB0111279D0 (en) 2001-05-10 2001-05-10 Radiolabelled liposomes
AT02769160T ATE430557T1 (de) 2001-05-10 2002-05-10 Liposomen
PCT/GB2002/002100 WO2002089771A1 (en) 2001-05-10 2002-05-10 Liposomes
EP02769160A EP1385480B1 (en) 2001-05-10 2002-05-10 Liposomes
JP2002586908A JP4629308B2 (ja) 2001-05-10 2002-05-10 リポソーム
US10/477,157 US20040170560A1 (en) 2001-05-10 2002-05-10 Liposomes
DE60232237T DE60232237D1 (de) 2001-05-10 2002-05-10 Liposomen
ES02769160T ES2323493T3 (es) 2001-05-10 2002-05-10 Liposomas.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0111279.6A GB0111279D0 (en) 2001-05-10 2001-05-10 Radiolabelled liposomes

Publications (1)

Publication Number Publication Date
GB0111279D0 true GB0111279D0 (en) 2001-06-27

Family

ID=9914262

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0111279.6A Ceased GB0111279D0 (en) 2001-05-10 2001-05-10 Radiolabelled liposomes

Country Status (8)

Country Link
US (1) US20040170560A1 (enExample)
EP (1) EP1385480B1 (enExample)
JP (1) JP4629308B2 (enExample)
AT (1) ATE430557T1 (enExample)
DE (1) DE60232237D1 (enExample)
ES (1) ES2323493T3 (enExample)
GB (1) GB0111279D0 (enExample)
WO (1) WO2002089771A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5355842B2 (ja) * 2002-12-31 2013-11-27 ザイダス ビーエスヴィ ファーマ プライベート リミテッド 非ペギレート化長循環性リポソーム
EP1694298B1 (en) * 2003-11-03 2010-06-09 Yissum Research Development Company, of The Hebrew University of Jerusalem Method for selecting cationic or anionic liposomes for treatment of a mucosa membrane, and kit comprising the same
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
US8790691B2 (en) * 2008-05-23 2014-07-29 The University Of British Columbia Modified drugs for use in liposomal nanoparticles
CN108165548B (zh) * 2008-09-22 2022-10-14 菲奥医药公司 减小大小的自递送RNAi化合物
AR076634A1 (es) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US10519504B2 (en) 2009-05-11 2019-12-31 Berg Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US9849173B2 (en) * 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
US11400058B2 (en) * 2010-03-12 2022-08-02 Berg Llc Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof
EP2694463B8 (en) 2011-04-04 2019-10-09 Berg LLC Treating central nervous system tumors with coenzyme q10
CA2834353A1 (en) * 2011-04-26 2012-11-01 Cedars-Sinai Medical Center Liposomal vancomycin for the treatment of mrsa infections
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
FR2979239A1 (fr) * 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
US20140023696A1 (en) * 2012-07-20 2014-01-23 Frederick Timothy Guilford Treatment for idiopathic pulmonary fibrosis
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) * 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
MX389323B (es) 2013-12-03 2025-03-20 Univ Northwestern Particulas liposomales, metodos para elaborarlas y sus usos.
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
KR102689262B1 (ko) 2014-09-05 2024-07-30 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
JP6741673B2 (ja) 2014-10-06 2020-08-19 イグジキュア, インコーポレーテッドExicure, Inc. 抗ｔｎｆ化合物
WO2016085986A1 (en) 2014-11-24 2016-06-02 Northwestern University High density lipoprptein nanoparticles for inflammation
CN105434368A (zh) * 2014-11-27 2016-03-30 广州白云山明兴制药有限公司 一种注射用还原型谷胱甘肽及其预冻方法
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
KR20200028997A (ko) 2017-07-13 2020-03-17 노오쓰웨스턴 유니버시티 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6137735A (ja) * 1984-07-31 1986-02-22 Terumo Corp ヘモグロビン含有リポソ−ムおよびその製造方法
WO1990012595A1 (en) * 1989-04-18 1990-11-01 Vestar, Inc. Liposomal targeting of ischemic tissue
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5143713A (en) * 1990-05-30 1992-09-01 Board Of Regents, The University Of Texas System 99m Tc labeled liposomes
WO1994012155A1 (en) * 1992-12-02 1994-06-09 Vestar, Inc. Antibiotic formulation and process
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
EP0825852B1 (en) * 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
JPH11171772A (ja) * 1997-12-11 1999-06-29 Sankyo Co Ltd 抗腫瘍薬のリポソーム化製剤
JP2002543134A (ja) * 1999-04-29 2002-12-17 アルザ・コーポレーション 薬物保持率を改善するためのリポソーム組成物
CA2340757A1 (en) * 1999-07-07 2001-01-18 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Delivery of liposomal-encapsulated antioxidants and applications thereof

Also Published As

Publication number Publication date
DE60232237D1 (de) 2009-06-18
ES2323493T3 (es) 2009-07-17
JP4629308B2 (ja) 2011-02-09
ATE430557T1 (de) 2009-05-15
WO2002089771A1 (en) 2002-11-14
EP1385480A1 (en) 2004-02-04
EP1385480B1 (en) 2009-05-06
JP2004529163A (ja) 2004-09-24
US20040170560A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
GB0111279D0 (en) Radiolabelled liposomes
PL344715A1 (en) Fixed oral dose composition featured by prolonged release of active substance
ES2130575T3 (es) Composiciones inmunogenicas mejoradas contra la gastrina 17 humana.
DE59707812D1 (de) Opioidantagonisthaltige galenische formulierung
PL341565A1 (en) Oral dosage form featured by pulse-type release of active substance
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
HUP9901199A3 (en) Tropane-derivatives, inhibiting neurotransmitter re-uptake, their preparation, pharmaceutical compositions containing them and use of the compounds
AU6011701A (en) Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
HUP9900605A3 (en) Lipopolyamines as transfection agents, preparation and use thereof and pharmaceutical compositions containing them
NZ314442A (en) Extended release formulation comprising venlafaxine hydrochloride, film coating composition
ATE321537T1 (de) Pharmazeutische zubereitung enthaltend doxazosin
EP1193270A3 (en) Pyrrolobenzodiazepines
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
ATE312080T1 (de) 2-chinolonen enthaltende arzneimittel
WO2002045769A3 (en) A bilayer structure which encapsulates multiple containment units and uses thereof
HUP0203844A3 (en) Compound with growth hormone releasing properties, pharmaceutical composition containing it and its use
ES2161292T3 (es) Composicion de higiene oral.
ATE315395T1 (de) Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten
WO2002048142A1 (en) Medicinal compositions having improved absorbability
SE9802937D0 (sv) Novel compounds
TW200509863A (en) Irradiation device for medical use
BR1100143A (pt) Composto, e, composição farmacêutica.
EP0863192A4 (en) HUMIDIFIER COMPOSITION, THIS CONTAINING BASE COMPOSITION AND COSMETIC MATERIAL OR EXTERNAL APPLICATION WHICH CONTAINS THIS HUMIDIFIER COMPOSITION
IL156069A0 (en) Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma
BG105862A (en) Light, extruded compositions containing a light, extrudable, ceramic carrier, methods for their use and preparartion

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)